Seeking Alpha

Par Pharma (PRX) +6.5% after a Delaware court rules five patents covering Santarus' (SNTS...

Par Pharma (PRX) +6.5% after a Delaware court rules five patents covering Santarus' (SNTS -31.9%) stomach drug Zegerid are invalid due to "obviousness." Analysts say Par Pharma's proposed generic is Zegerid's only challenger, and while it hasn't received FDA approval, the ruling removes a large hurdle.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs